Print this Content
Email this Content

Appointed: 2002

Mikkael Sekeres, M.D., M.S.

(216) 445-9353

Mikkael Sekeres, M.D., M.S.

Department: Hematologic Oncology and Blood Disorders
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
WorkPhone:(216) 445-9353

Mikkael Sekeres, M.D., M.S.

Department: Translational Hematology and Oncology Research
Location: Cleveland Clinic Main Campus
Mail Code R35
9500 Euclid Avenue
Cleveland, OH 44195
WorkPhone:(216) 445-9353

Professional Highlights

  • Co-Chair, Medical Advisory Board, Aplastic Anemia and Myelodysplastic Syndromes International Foundation
  • Member, National Cancer Institute PDQ Adult Treatment Editorial Board
  • Reviewer, Blood, Cancer, Lancet, Clinical Cancer Research, Oncology, Leukemia Research, British Journal of Haematology, Cancer Investigation
  • Member, Oncologic Drugs Advisory Committee, F.D.A.
  • Director, Myelodysplastic Syndromes Program Reviewer, Journal of Clinical Oncology

Education & Fellowships

Fellowship - Dana-Farber Cancer Institute
Hematology/Oncology
Boston, MA USA
2002
Residency - Massachusetts General Hospital
Internal Medicine
Boston, MA USA
1999
Graduate - University of Pennsylvania
Clinical Epidemiology
Philadelphia, PA USA
1996
Medical School - University of Pennsylvania School of Medicine
Philadelphia, PA USA
1996
Undergraduate - University of Pennsylvania
Philadelphia, PA USA
1991

Certifications

  • Internal Medicine- Medical Oncology

Specialty Interests

Acute Myeloid Leukemia, bone marrow failure syndromes/disorders, chronic myelogenous leukemia, Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasms, Hairy Cell Leukemia, Chronic Lymphocytic Leukemia (CLL), Acute Lymphocytic Leukemia (ALL)

Awards & Honors

  • Phi Beta Kappa, University of Pennsylvania, 1991
  • Magna cum Laude, University of Pennsylvania, 1991
  • “Bridging the Gaps” Community Service Achievement Award, University of Pennsylvania School of Medicine, 1995
  • Alpha Omega Alpha, University of Pennsylvania School of Medicine, 1995
  • American Federation for Clinical Research Award, University of Pennsylvania School of Medicine, 1996
  • Study Sections, RFA-HL-04-033 (Myelodysplastic Syndromes) and RFA-HL-04-034 (Myeloproliferative Disorders), National Heart, Lung and Blood Institute, 2005
  • Moderator, American Society of Hematology Annual Meeting, Myelodysplastic Syndromes: Clinical Studies session, 2005, 2007
  • Moderator, American Society of Hematology Annual Meeting, Acute Myeloid Leukemia: Therapies Excluding Transplant, 2008
  • Scientific Discussant, American Society of Clinical Oncology Annual Meeting: Leukemia, Myelodysplasia, and Transplantation Session, 2008
  • Education Session chair, American Association of Blood Bankers Annual Meeting: Myelodysplastic Syndromes, 2009
  • Education Session chair, American Society of Hematology Annual Meeting: Myelodysplastic Syndromes, 2009
  • Best Doctors, Cleveland Magazine, 2008, 2009

Additional Training

  • Coursework, Harvard School of Public Health, 2000
  •  Leading in Healthcare course, Cleveland Clinic, 2008

Memberships

  • American Society of Hematology
  • Southwest Oncology Group, Leukemia Committee
  • American Society of Clinical Oncology

Treatment & Services

Specialty in Diseases and Conditions

Industry Relationships

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical education about recent trends. The collaborations are reviewed as part of the Cleveland Clinic’s procedures. The Cleveland Clinic publicly discloses payments to its physicians and scientists for speaking and consulting of $5,000 or more per year, and any equity, royalties, and fiduciary relationships in companies with which they collaborate. In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its doctors’ connections with industry and those of their immediate family members. As of 7/31/2008, Dr. Sekeres has reported the financial relationships with the companies listed below. Patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic’s policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting. Dr. Sekeres receives fees of $5,000 or more per year as a paid consultant or speaker for the following companies:

Network for Medical Communications and Research

Oncology Associates, LLC

Celgen Corporation

Languages Spoken

  • English